Randomised controlled trial of fluoxetine versus naltrexone in compulsive sexual behaviour disorder.

Authors

Josephine Savard, Marta Piwowar, Roberth Adebahr, Markus Byström, Jonas Hallberg, Cecilia Dhejne, Katarina Görts Öberg, Jussi Jokinen

Published in

BMJ mental health. Volume 29. Issue 1. Oct 06, 2026. Epub Oct 06, 2026.

Abstract

Compulsive sexual behaviour disorder (CSBD), characterised by preoccupation with and loss of control over sexual behaviours, is associated with negative consequences in several areas of life. Evidence for pharmacological treatment remains limited, with only two previous randomised controlled trials and no studies comparing fluoxetine and naltrexone.
To investigate whether naltrexone was more efficient and tolerable than fluoxetine in the treatment of CSBD.
In this open-label superiority trial, 80 participants diagnosed with CSBD according to International Classification of Diseases-11 criteria were randomly assigned (1:1) to receive fluoxetine (starting dose 20 mg/day) or naltrexone (starting dose 25 mg/day) for 8 weeks followed by 6 weeks without treatment. Symptom severity was recurringly assessed using the Hypersexual Disorder: Current Assessment Scale (HD:CAS). Linear mixed models were used for intention-to-treat and per-protocol analyses of treatment effects.
79 men and 1 woman were randomised to receive fluoxetine (n=40) or naltrexone (n=40). Analysis showed no statistically significant difference in HD:CAS score reduction between treatments at primary endpoint; naltrexone was not superior to fluoxetine. However, participants in the two treatment groups showed different patterns of symptom improvement over time.Two participants (5.1%) receiving fluoxetine were withdrawn due to adverse events (urticaria and elevated liver enzymes) and four participants (10.3%) discontinued treatment; six participants (15%) receiving naltrexone discontinued treatment.
Although no statistically significant between-group difference was observed at week 8, symptom trajectories and adverse effect profiles differed between groups.
Symptom-change patterns and adverse effect profiles may guide individualised treatment decisions.

PMID:
42838712
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.